Overview

Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors plan better treatment for patients receiving isotretinoin. PURPOSE: This clinical trial is studying the side effects and best dose of isotretinoin in treating young patients with high-risk neuroblastoma.
Phase:
N/A
Details
Lead Sponsor:
Children's Cancer and Leukaemia Group
Treatments:
Isotretinoin